Ordering
Available Variants10 mg
CHA.84013-10mg
Price
€65.20
Available – Dispatch in 14 days
50 mg
CHA.84013-50mg
Price
€180.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.84013-10mg | €65.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.84013-50mg | €180.80 |
≥98% (HPLC), ErbB2 dual inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C24H25ClFN5O3 |
|---|---|
| CAS Number | 850140-72-6 |
| Molecular Weight | 485.94 |
| NACRES | NA.77 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD12407405 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H319,H373 |
| pcodes | P260 - P264 - P270 - P301 + P312 - P305 + P351 + P338 - P314 |
| Hazard Classifications | Acute Tox. 4 Oral - Eye Irrit. 2 - STOT RE 2 |
| target_organs | Kidney,Skin |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Afatinib, with the chemical name N-[4-(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-(methoxyethoxy)quinazoline, is a potent and selective inhibitor of the ErbB family of tyrosine kinases. Its chemical formula is C32H33ClFN5O3 and its CAS number is 850140-72-6. Afatinib has been shown to irreversibly bind to and inhibit the activity of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4, which are involved in the regulation of cell growth and division. By inhibiting these kinases, afatinib has demonstrated efficacy in the treatment of non-small cell lung cancer, particularly in patients with specific EGFR mutations. Its pharmacokinetic properties and mechanism of action make it a valuable therapeutic option for the management of this disease. Afatinib is administered orally and its efficacy and safety have been evaluated in several clinical trials.
